Skip to main content

Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

The final receipt date for PAR-21-070, Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed), will be March 17, 2023.
This program supports bi-phasic grants focused on early stage diagnostics development for rapid, simple, sensitive, and cost-effective assays that would allow individuals to monitor themselves for initial HIV infection and/or HIV rebound following antiretroviral treatment.

  • Strategies may include either the initial development of a novel technology or adaptation of an existing technology to detect HIV from finger stick blood or other biospecimen.
  • Proposed studies are expected to be at the discovery and feasibility stage, designed to show potential efficacy in the detection of HIV and feasibility as a self-test platform.
  • Proposed studies should emphasize innovation and exploratory research with a focus on qualitative or semi-quantitative HIV detection and assay development.
  • Applications should include plans to obtain meaningful end-user input on assay performance and usability during early-stage assay development.

Also note that this announcement has been updated to include the new NIH Data Management and Sharing Plan requirement (DMS).

See the announcement for additional information and instructions (, and please circulate widely among potentially interested colleagues.

Interested investigators are encouraged to contact Dr. Diane Lawrence ( or Dr. Naana Cleland ( for guidance prior to the March 17 submission deadline.